miR-301a expression is correlated with tumor progression and a reduced KPS, with exosomal levels dynamically changing following tumor resection and recurrence, making it a valuable biomarker for disease monitoring.77 Additionally, exosomal miR-210, miR-5194, and miR-449 target key genes in the EGFR and cellular mesenchymal epithelial transition (c-MET) signaling pathways and are correlated with histopathological grade and GBM aggressiveness.78 Table S6 presents the miRNAs that serve as biomarkers associated with GBM pathogenesis. The gene discussed is EGFR; the disease is glioblastoma.